SAVA Stock Plummets After Alzheimer’s Drug Fails Phase 3 Trial
A Crushing Blow to Cassava Sciences and Alzheimer’s Hopes Cassava Sciences (SAVA) stock experienced a devastating plunge on Monday, November 25th, 2024, plummeting over 80% and erasing billions in market capitalization. This dramatic downturn followed the announcement of the failure of its leading Alzheimer’s drug candidate, simufilam, in a pivotal Phase 3 clinical trial. The…